AU2009317279B2 - Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate - Google Patents

Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate Download PDF

Info

Publication number
AU2009317279B2
AU2009317279B2 AU2009317279A AU2009317279A AU2009317279B2 AU 2009317279 B2 AU2009317279 B2 AU 2009317279B2 AU 2009317279 A AU2009317279 A AU 2009317279A AU 2009317279 A AU2009317279 A AU 2009317279A AU 2009317279 B2 AU2009317279 B2 AU 2009317279B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
controlled release
present
comprised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009317279A
Other languages
English (en)
Other versions
AU2009317279A1 (en
Inventor
Monique Berwaer
Frederic Eeckman
Domenico Fanara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of AU2009317279A1 publication Critical patent/AU2009317279A1/en
Application granted granted Critical
Publication of AU2009317279B2 publication Critical patent/AU2009317279B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2009317279A 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate Active AU2009317279B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08105817.4 2008-11-18
EP08105817 2008-11-18
EP09100311.1 2009-06-02
EP09100311 2009-06-02
PCT/EP2009/065270 WO2010057869A1 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Publications (2)

Publication Number Publication Date
AU2009317279A1 AU2009317279A1 (en) 2010-05-27
AU2009317279B2 true AU2009317279B2 (en) 2013-10-24

Family

ID=41395028

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009317279A Active AU2009317279B2 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Country Status (18)

Country Link
US (1) US8460712B2 (enExample)
EP (1) EP2358361B1 (enExample)
JP (2) JP5954889B2 (enExample)
KR (2) KR20110089184A (enExample)
CN (2) CN104083341A (enExample)
AU (1) AU2009317279B2 (enExample)
BR (1) BRPI0921301A2 (enExample)
CA (1) CA2741038C (enExample)
DK (1) DK2358361T3 (enExample)
EA (1) EA019583B1 (enExample)
ES (1) ES2602606T3 (enExample)
HK (1) HK1198288A1 (enExample)
HU (1) HUE030963T2 (enExample)
IL (1) IL212271A (enExample)
MX (1) MX356281B (enExample)
PL (1) PL2358361T3 (enExample)
PT (1) PT2358361T (enExample)
WO (1) WO2010057869A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2741041C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
WO2022238401A1 (en) * 2021-05-11 2022-11-17 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
WO2025128057A1 (en) * 2023-12-13 2025-06-19 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A sachet formulation comprising brivaracetam

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
WO2008027993A2 (en) * 2006-08-31 2008-03-06 Eurand, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
WO2009036811A1 (en) * 2007-09-21 2009-03-26 Evonik Röhm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
JP5739080B2 (ja) 2005-01-27 2015-06-24 アレムビック・リミテッドＡｌｅｍｂｉｃ Ｌｉｍｉｔｅｄ レベチラセタムの徐放性製剤
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
EP1909770B1 (en) 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
EP1863453A2 (en) * 2005-03-29 2007-12-12 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
ES2474945T3 (es) * 2008-03-03 2014-07-10 Ucb Pharma, S.A. Soluciones farmacéuticas, procedimiento de preparación y usos terapéuticos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
WO2008027993A2 (en) * 2006-08-31 2008-03-06 Eurand, Inc. Drug delivery systems comprising solid solutions of weakly basic drugs
WO2009036811A1 (en) * 2007-09-21 2009-03-26 Evonik Röhm Gmbh Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol

Also Published As

Publication number Publication date
CN104083341A (zh) 2014-10-08
HK1198288A1 (en) 2015-03-27
JP5954889B2 (ja) 2016-07-20
EA201100753A1 (ru) 2012-01-30
DK2358361T3 (en) 2016-12-12
BRPI0921301A2 (pt) 2015-12-29
KR20110089184A (ko) 2011-08-04
US8460712B2 (en) 2013-06-11
CA2741038A1 (en) 2010-05-27
JP2015143256A (ja) 2015-08-06
MX356281B (es) 2018-05-22
KR20170007528A (ko) 2017-01-18
AU2009317279A1 (en) 2010-05-27
EA019583B1 (ru) 2014-04-30
EP2358361B1 (en) 2016-09-14
WO2010057869A1 (en) 2010-05-27
CA2741038C (en) 2015-01-13
ES2602606T3 (es) 2017-02-21
IL212271A (en) 2016-10-31
JP2012509356A (ja) 2012-04-19
IL212271A0 (en) 2011-06-30
HUE030963T2 (en) 2017-06-28
EP2358361A1 (en) 2011-08-24
US20110274762A1 (en) 2011-11-10
MX2011004572A (es) 2011-06-17
KR101788804B1 (ko) 2017-10-20
CN102215828A (zh) 2011-10-12
PL2358361T3 (pl) 2017-02-28
PT2358361T (pt) 2016-11-18

Similar Documents

Publication Publication Date Title
AU2009317280B2 (en) Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
US8563036B2 (en) Pharmaceutical compositions comprising Brivaracetam
AU2010209790B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
AU2009317279B2 (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159503B (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)